Related Experiment Video
Updated: Jul 22, 2025
09:44
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
223
Neural Cells for Neurodegenerative Diseases in Clinical Trials
Yiping Fan1,2,3, Eyleen L K Goh4, Jerry Kok Yen Chan1,2,3
1Department of Reproductive Medicine, KK Women's and Children's Hospital, Singapore, Singapore.
Stem Cells Translational Medicine
|July 24, 2023
Summary
Cellular therapies show promise for neurodegenerative diseases (ND), with numerous clinical trials underway using various cell types. Further randomized studies are needed to confirm efficacy, though cost and rare disease prevalence pose challenges.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Clinical Trials
Background:
- Neurodegenerative diseases (ND) encompass a range of debilitating central and peripheral nervous system disorders with no current cure.
- Current treatments for ND focus on slowing disease progression and managing symptoms.
Approach:
- This review compiles data from 150 clinical trials investigating cellular therapies for seven distinct ND.
- The trials utilize diverse cell types, including neural stem progenitors, differentiated neural cells, and non-neural cells derived from various sources like embryonic and induced pluripotent stem cells.
Key Points:
- 33 trials involved neural stem progenitors, 8 used differentiated neural cells, and 109 employed non-neural cells.
- Early-phase clinical trials have yielded encouraging results, suggesting therapeutic potential.
- Cellular therapies offer a novel approach to treating neurodegenerative conditions.
Conclusions:
- Encouraging outcomes from early trials necessitate further investigation in randomized controlled settings.
- The high cost of trials and the rarity of certain neurodegenerative diseases may impede definitive large-scale studies.
More Related Videos
Related Concept Videos
01:37Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
01:15Neurogenesis and Regeneration of Nervous Tissue
860
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
860
01:21EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
01:15Parkinson's Disease: Overview
599
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
599